The UK’s first high-security robotic AI laboratory designed to accelerate the discovery of drugs and vaccines for infectious diseases has opened in Liverpool. The £20 million Liverpool Accelerate Laboratory has been developed through the Infection Innovation Consortium: iiCON, which advances pioneering infection R&D through collaboration between industry, researchers and the NHS. It… Read More
A new resource is now available to download for free. MASLD drug development is limited by models that don’t reflect human liver biology. HUB’s patient-derived liver organoids retain donor genetics, architecture and physiology. Download the Factsheet to learn: How organoids recapitulate steatosis and fibrosis Which readouts support target validation… Read More
Darren Heywood, Senior Product Manager at Promega UK, examines assay formats built specifically for 3D measurements. A 3D microtissue, such as a spheroid or organoid, is not a monolayer with more cells. These are three-dimensional… Read More
Neil Bhowmick, Chief Scientific Officer at Kairos Pharma, explores the biology of cancer drug resistance and the opportunities to overcome it. Despite extraordinary advancements in how we treat cancer, ranging from cytotoxic chemotherapy to precision immunotherapies, one fundamental barrier consistently impedes… Read More
This paid-for advertorial by Lumencor appeared in DDW Volume 27 – Issue 3, Summer 2026. Studying neurodevelopmental disorders like schizophrenia is limited by model complexity and tissue access. Advanced stem cell models combined with high-speed imaging now enable scalable insight into neuronal activity and network behaviour. … Read More
By Carolina Lucchesi, Principal Scientist and Head of Microphysiological Systems, ATCC. Across the world, regulators are sending a consistent signal: the era of animal-only preclinical testing is drawing to a close. In the United States, the Food and Drug Administration (FDA) has committed to phasing out animal testing requirements1. The European Union and United Kingdom are moving in the… Read More
Researchers have developed a molecular switch that wakes lung cancer cells up from a protective dormant state so that they are more accessible for treatment. Tumour cells can lapse into a sleep-like state and thereby evade the destructive effect of cancer drugs. Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a UK group accelerated efforts to develop a vaccine for Ebolavirus. Elsewhere,… Read More
News round-up for 25–29 May by Bruno Quinney, Content Team at DDW. This week, a UK group has accelerated efforts to develop a vaccine for Ebolavirus. Elsewhere, significant findings in colorectal and brain cancer could shape future cancer treatments. The top stories: UK group steps… Read More
Brain cancer could be treated more easily using stem cells from the lining of the mouth, new research suggests. Scientists at the University of Reading found that when stem cells from the mouth were transplanted into mouse brain tissue, they slowed cancer growth and reduced the size… Read More
A new Fact Sheet is now available to download from HUB Organoids (now part of Merck). Get earlier, mechanistic insight into DILI risk with HUB Organoids’ human liver organoid platform: Donor-diverse liver organoid biobank Multiparametric live-cell assay: mitochondrial dysfunction, oxidative stress, lipid dysregulation,viability Supports lead optimisation and safer candidate selection… Read More
Dr Mark Eccleston, Director of Inaphaea, discusses how patient-derived 3D models can bridge the translational divide in oncology. Drug development is a… Read More
James L Sherley, MD, PhD, explores how a new method for quantifying stem cells in mesenchymal tissue samples can lead to better drug development for stem cell therapies. Mesenchymal tissue cell samples are considered incredibly promising for the development of new stem cell therapies. These samples can be based on bone… Read More
An international collaboration is set to evaluate chemotherapeutic toxicity in human organoids, aiming to generate safer and more effective cancer therapeutics. iXCells Biotechnologies, a provider of human cell-based solutions and iPSC services, has announced it has joined the collaboration alongside Rosebud Biosciences, Kantify and Incite. The project will… Read More
In this new whitepaper, discover how ProBio accelerates bispecific antibody development with optimised cell line strategies. This guide highlights proven methods such as two-vector expression systems and NGS‑enabled clone selection to improve purity, productivity, and manufacturing robustness. You will learn: How to reduce bispecific antibody impurities through chain‑ratio optimisation Methods… Read More
Stem cell technologies company Axol Bioscience has acquired the ophthalmology business of Newcells Biotech. The acquisition of Newcells’ ophthalmology business includes its specialist team, facilities and intellectual property related to supply of proprietary iPSC-derived products and ophthalmology research services to biopharma, biotechnology and CRO customers across Europe and… Read More
